Gilead Calls Immunology Its Third Pillar — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Gilead Sciences executives have been emphatically bullish at recent investor conferences about the biotech's years-long push to develop drugs for inflammatory and autoimmune diseases.
- Gilead CFO Andy Dickinson told investors at the Cantor Global Healthcare Conference earlier this month that inflammation and immunology is one of three core scientific focus areas.
- Dickinson described I&I as "the third leg of the stool," alongside virology and oncology, calling Gilead "the largest virology company" with "a robust oncology business" already built.
- Dickinson framed the I&I business as one Gilead is actively growing, positioning it as a strategic priority for investors evaluating the pipeline.
Why it matters: For investors evaluating Gilead's pipeline, the company has now publicly mapped a three-pillar scientific strategy — virology, oncology, and inflammation/immunology — with the I&I business described as actively growing, making it a stated priority alongside two already-established franchises.
Ask SkimNews
